Maitake and Glucose Tolerance: The Georgetown Research Decoded

Maitake & Blood Sugar / Diabetes

30–63% fasting glucose decline

That's the range observed in 7 Type 2 diabetic patients taking maitake SX-fraction over two to four weeks, the most informative human signal in the entire Georgetown research body.

Konno, Int J Gen Med, 2013

5

Georgetown animal studies, 2002–2012

3+

validated rodent disease models tested

7

T2DM patients in the only human pilot

Konno, Int J Gen Med, 2013

View as image ↗

Search "Georgetown maitake study glucose tolerance" and you'll find dozens of sites describing the research as though it were human clinical trials. Some use phrases like "Georgetown University clinical research confirms maitake's glucose-lowering effects in diabetic patients." The research is real, and the findings are genuinely interesting. But the word "clinical" is doing a lot of misleading work. Every study conducted at Georgetown's Physiology department tested maitake fractions in animal models. Understanding what those experiments actually showed, what compound they identified, and how a separate line of research eventually produced a small human observation is the only honest way to evaluate what the evidence means.

Maitake, a large fan-shaped mushroom also known as Grifola frondosa, has been tested in several rodent models of insulin resistance and diabetes. You can read a full overview of the mushroom in What Is Maitake Mushroom?. The results across metabolic models are consistent. But "consistent in rodents" and "demonstrated in humans" are different categories of evidence, and that distinction matters for calibrating how much weight to put on these findings.

The Georgetown Research Was Animal Studies, Not Human Trials

Dr. Harry Preuss and colleagues at Georgetown University's Department of Physiology published five papers on maitake's metabolic effects between 2002 and 2012. The research program was coherent and systematically designed. It was also conducted entirely in animal models.

The animals used across the five studies were: KK mice (a strain that spontaneously develops obesity and insulin resistance), Zucker fatty rats (a classic model for metabolic syndrome and insulin resistance), streptozotocin-induced diabetic rats (a chemically induced diabetes model targeting the insulin-producing beta cells of the pancreas), and spontaneously hypertensive rats (a hypertension model that develops insulin resistance as a complication).

These are validated research models used across pharmaceutical development. They are not exotic or low-quality science. The Georgetown work was carefully designed. The issue is that this research is frequently described as "clinical trials" when it was preclinical work in rodents. That distinction is especially important in blood sugar research, because many compounds that lower glucose in rodent diabetes models fail to produce the same effect in humans. Knowing exactly what these five studies found, and what they cannot tell us, is the foundation for honest evaluation.

What the Georgetown Animal Studies Found

The first Georgetown maitake study appeared in 2002 in Diabetes, Obesity and Metabolism. Manohar and colleagues gave a water-soluble maitake extract called FXM to KK mice, a genetically insulin-resistant strain, and measured circulating glucose and insulin.^[2]

Both fell.

That simultaneous result deserves attention. When a drug lowers blood sugar by triggering more insulin secretion (sulfonylureas work this way), glucose falls while insulin rises; the pancreas is pumping out more of it. When something improves how cells respond to insulin that is already present, the body needs less insulin to move glucose out of the bloodstream. Both glucose and insulin fall together. Manohar's result matched the second pattern: the maitake extract appeared to be making cells more responsive to insulin, not stimulating the pancreas to release more.

Two more papers from the same group appeared the same year. Talpur and colleagues tested maitake fractions in Zucker fatty rats, a model for obesity and metabolic syndrome.^[3] Blood glucose fell. Blood pressure fell too. A parallel study tested whole maitake powder and fractions in both spontaneously hypertensive rats and Zucker fatty rats simultaneously.^[4] The glucose-lowering and blood pressure-lowering effects appeared in both strains. The consistency across two separate rodent models strengthened the finding, even if the animal-to-human translation remained unresolved.

The dual glucose and blood pressure effect across multiple studies is worth noting because insulin resistance drives both conditions through shared pathways. Improving insulin sensitivity tends to lower both blood sugar and blood vessel tone simultaneously. For the detailed blood pressure research, see Maitake and Blood Pressure: Antihypertensive Research.

A separate set of glucose tolerance data came from Horio and Ohtsuru, working in Japan in 2001. They used oral glucose tolerance testing in streptozotocin-induced diabetic rats, the same type of test used in human prediabetes screening. After a sugar challenge, the rats that received maitake extract showed lower blood glucose at each measurement point compared to controls.^[1] The term "glucose tolerance" in the title of many Georgetown-adjacent articles refers to exactly this kind of result: the body clearing a sugar load more efficiently. This Japanese study contributed the clearest glucose tolerance framing, though it used a different rodent model from the Georgetown work.

Why Glucose and Insulin Falling Together Is the Key Finding

The Manohar 2002 result deserves its own section because it reveals which mechanism is operating, and that question has direct clinical implications.

Two categories of blood sugar drugs exist: those that push the pancreas to release more insulin, and those that help the body use existing insulin more efficiently. The first category includes sulfonylureas. The second includes metformin.

Sulfonylureas lower glucose reliably but carry a risk of hypoglycemia, because they work regardless of whether the body actually needs more insulin. Metformin lowers glucose by improving how muscle, liver, and fat cells respond to insulin, without forcing extra insulin secretion. When something lowers glucose by insulin sensitization, the risk profile differs from secretion-stimulating drugs.

When Manohar's team measured KK mice receiving FXM and found that both glucose and insulin fell together, they were observing the signature of insulin sensitization. The maitake extract appeared to be helping cells respond to insulin more efficiently, not stimulating the pancreas to produce more.^[2]

This is mechanistically significant even if it cannot be translated directly into human recommendations. It identifies the type of effect maitake might be producing, and it aligns with the molecular pathway that later research in cells confirmed. See Maitake SX-Fraction and Insulin Sensitivity for the full mechanistic breakdown.

Isolating the Active Compound: How SX-Fraction Was Found

After four years of consistent metabolic effects in rodent models, the Georgetown group's next question was identifying which component of maitake was responsible.

Maitake is a complex food. It contains polysaccharides (including the immune-modulating D-fraction, a beta-glucan), glycoproteins, organic acids, and dozens of other compounds. The early Georgetown studies used whole maitake fractions or water-soluble extracts. Pinning down the specific molecule carrying the glucose effect required targeted work.

Preuss and colleagues published the answer in 2007 in Molecular and Cellular Biochemistry. They isolated a specific glycoprotein fraction and tested it in spontaneously hypertensive rats. This glycoprotein, which became known as SX-fraction, enhanced insulin-hypoglycemic activity and reduced blood pressure.^[5]

The 2012 Preuss paper in the Journal of Medicinal Food added a comparative dimension. SX-fraction was tested against metformin and an ACE inhibitor in streptozotocin-induced diabetic rats. Both drug comparisons target either blood sugar or blood pressure specifically. SX-fraction reduced blood glucose and blood pressure consistently across measurements.^[6] In the insulin sensitivity measurement specifically, SX-fraction was the only compound that showed consistent improvement; the drugs did not match it on that particular metric.

This does not establish that SX-fraction is superior to metformin in humans. The animal-to-human translation has not been tested in a rigorous trial. What it does establish in the animal model is that the mechanism is genuinely insulin-sensitizing in a way that differs from how standard drugs work. That is a meaningful mechanistic signal.

One distinction is worth stating clearly: SX-fraction is a glycoprotein, not a polysaccharide. Maitake's D-fraction, the immune-modulating extract most commonly marketed for immune support, is a beta-glucan (a type of polysaccharide). These are completely different molecules with completely different mechanisms of action. D-fraction activates immune cells. SX-fraction appears to act on the insulin signaling pathway. They are sometimes conflated in supplement marketing, but they represent distinct pharmacological entities. For broader context on how maitake works at the molecular level, see The Pharmacology of Grifola frondosa: How Maitake Works.

From Rat Cages to Muscle Cells to Seven Patients

The Georgetown research established what happened physiologically in animals: blood glucose fell, blood pressure fell, and the pattern pointed to insulin sensitization. What it did not explain was the molecular mechanism, specifically which cellular machinery was being activated and by what pathway.

That question was answered by Dr. Sensuke Konno in a 2013 paper in the International Journal of General Medicine.^[7]

Konno first tested SX-fraction in L6 cells, a line of skeletal muscle cells widely used to study insulin signaling. When SX-fraction was added to these cells, it activated two proteins: the insulin receptor (IR) and insulin receptor substrate-1 (IRS-1). These two proteins are the first and second steps of the cascade that ultimately moves GLUT4 to the surface of muscle cells. GLUT4 is a glucose transporter, the channel that allows glucose to move from the bloodstream into the cell. Without GLUT4 on the cell surface, glucose stays circulating in the blood.

In plain terms: SX-fraction appeared to trigger the first two steps of the process cells use to clear glucose from the blood. This is the same pathway that insulin itself activates. It explains why the Georgetown animal studies showed glucose falling, and why insulin also fell: less of it was needed once cells were responding more efficiently.

In the same 2013 paper, Konno reported a clinical pilot. Seven Type 2 diabetic patients already taking oral diabetes medications received SX-fraction supplementation and were followed for two to four weeks. Fasting blood glucose declined by 30 to 63 percent across the patients.^[7]

That range is notable. It also requires careful interpretation. This was not a controlled trial. There was no placebo group. All patients were already on diabetes medications. The duration was short. Seven patients cannot support broad conclusions about how the compound would perform across diverse populations. Konno himself described this as pilot data requiring confirmation in larger, randomized trials.

But it is real human data, which is more than most botanical compounds at this research stage can claim. Seven patients showed large declines in fasting blood glucose while taking a pharmacologically characterized compound whose mechanism had just been confirmed in human muscle cells.

Konno published a comprehensive review of all SX-fraction research in World Journal of Diabetes in 2020, synthesizing the Georgetown animal work, his own cell research, and the pilot human data.^[8] The review concluded that SX-fraction appears safe in the doses studied, the mechanism is pharmacologically plausible, and the human signal is encouraging, but larger randomized trials are needed before clinical conclusions can be drawn.

The Two-Patient Letter That Became "Clinical Evidence"

Before Konno's 2013 7-patient pilot, the only published human data on maitake and glucose was a 2001 letter to the editor in the Journal of Orthomolecular Medicine. Konno and colleagues reported that two patients with Type 2 diabetes showed approximately 30% reductions in blood glucose while taking whole maitake mushroom (Konno S et al., J Orthomolecular Med, 2001, PMID: 11903406).

A letter to the editor is not a clinical trial. It has no methodology section, no defined dosing protocol, no control group, no randomization, and no formal statistical analysis. It describes the observation of two patients, anecdotally, in a brief communication.

This letter is cited across dozens of supplement websites as "clinical research showing 30% glucose reduction" and "Georgetown-associated human evidence." Some sites describe it as a clinical trial. It is not. The 30% number may accurately reflect what those two patients experienced. Two patients cannot form the basis for population-level conclusions, and a letter to the editor is not a clinical study.

Understanding this is worth the space it takes, because the 30% claim is one of the most widely circulated pieces of maitake glucose evidence. When you trace it back, it comes from a 2-patient letter written by the same researcher who later published the 7-patient pilot. The letter is honest about its limitations. The sites that cite it are not.

What This Body of Research Actually Established

Taken as a whole, the Georgetown research and Konno's subsequent mechanistic work constitute a meaningful body of preclinical and early human evidence.

The animal findings are internally consistent. Five studies across four rodent models, all showing glucose-lowering and blood pressure-lowering effects through an insulin-sensitizing mechanism, represent a coherent preclinical picture. SX-fraction has been identified as the likely active glycoprotein, its molecular mechanism has been confirmed in human skeletal muscle cells, and a 7-patient pilot produced the first human signal.

What this body of work does not establish: that maitake lowers blood glucose in humans at a population level, that SX-fraction is effective across diverse patient populations, or that the effect is safe and sufficient when used alongside or instead of standard diabetes medications. The gap between "consistent animal findings plus a 7-patient pilot" and "proven human intervention" is real. It applies to most botanical compounds in metabolic research and reflects the absence of adequately powered human trials, not a failure of the preclinical science.

The Preuss group conducted legitimate, peer-reviewed work using validated models. The mechanistic work by Konno follows directly from those findings. The honest reading of this evidence base: promising enough to warrant a properly designed human trial, not yet sufficient to draw conclusions about clinical use.

For the full picture of how maitake compounds affect glucose metabolism at the molecular level, including the newer gut microbiota research, see How Maitake Affects Glucose Metabolism. For the broader clinical evidence picture on Type 2 diabetes, including Konno 2013 in full context, see Maitake for Type 2 Diabetes: Clinical Evidence and Mechanisms. The broader glycemic research is summarized in Maitake and Blood Sugar: Research on Glycemic Control. The metabolic connection between insulin resistance and heart disease is covered in Maitake and Cardiovascular Risk Reduction.

The Bottom Line

The Georgetown University maitake research consisted of five animal studies published 2002 to 2012, using KK mice, Zucker fatty rats, streptozotocin-induced diabetic rats, and spontaneously hypertensive rats. The findings were consistent: maitake fractions, and specifically SX-fraction, lowered blood glucose and blood pressure through insulin sensitization rather than insulin secretion. Konno (2013) confirmed the mechanism in skeletal muscle cells via the insulin receptor and IRS-1 pathway, and reported a 30–63% fasting glucose decline in 7 T2DM patients. The only published human data on whole maitake and glucose tolerance is a 2-patient letter to the editor from 2001. No randomized controlled trials in humans have been published. The preclinical evidence is coherent and mechanistically grounded; human trial confirmation is still absent.

Frequently Asked Questions

What did Georgetown University find about maitake?

Georgetown's Department of Physiology, led by Dr. Harry Preuss, published five studies (2002–2012) testing maitake fractions in rodent models of diabetes and insulin resistance. The studies consistently found reductions in blood glucose and blood pressure across KK mice, Zucker fatty rats, streptozotocin-induced diabetic rats, and spontaneously hypertensive rats. All research was conducted in animal models, not human subjects.

What is the Georgetown maitake study?

The phrase refers to a series of animal experiments published by Dr. Harry Preuss and colleagues at Georgetown University between 2002 and 2012. The studies used validated rodent disease models to characterize how maitake fractions affect blood glucose and blood pressure, ultimately identifying SX-fraction, a specific glycoprotein, as the likely active compound. These are not human clinical trials.

Is there clinical evidence for maitake improving glucose tolerance?

Human data is limited. A 2013 paper by Konno reported a 30–63% decline in fasting blood glucose in 7 Type 2 diabetic patients taking SX-fraction over two to four weeks, a pilot observation without a control group (Konno, Int J Gen Med, 2013). A 2001 letter to the editor described approximately 30% glucose reduction in 2 patients taking whole maitake. No randomized controlled trials in humans have been published.

Did maitake pass clinical trials for diabetes?

No. No randomized controlled trials testing maitake for diabetes have been published as of 2024. The human evidence consists of one 7-patient pilot observation (Konno, 2013) and one 2-patient letter to the editor (Konno et al., 2001). The extensive Georgetown animal research established preclinical evidence across multiple models but was not conducted in humans.

What is maitake SX-fraction and where was it studied?

SX-fraction is a water-soluble glycoprotein isolated from maitake mushroom. It is distinct from D-fraction, which is a beta-glucan polysaccharide that acts on the immune system. SX-fraction was identified as the glucose-lowering active compound through Georgetown University animal research by Preuss and colleagues (2007, 2012). Its mechanism, specifically activating the insulin receptor and IRS-1 in skeletal muscle cells and triggering the downstream GLUT4 pathway, was confirmed in cell experiments and a 7-patient pilot by Dr. Sensuke Konno (2013, 2020).

Sources & References

1. 1RTHM-00035·Horio, H et al. (2001). “Maitake (Grifola frondosa) improve glucose tolerance of experimental diabetic rats..” Journal of nutritional science and vitaminology.Study breakdown →PubMed →↩
2. 2RTHM-00097·Manohar, V et al. (2002). “Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice..” Diabetes.Study breakdown →PubMed →↩
3. 3RTHM-00052·Talpur, Nadeem et al. (2002). “Effects of Maitake mushroom fractions on blood pressure of Zucker fatty rats..” Research communications in molecular pathology and pharmacology.Study breakdown →PubMed →↩
4. 4RTHM-00053·Talpur, Nadeem A et al. (2002). “Antihypertensive and metabolic effects of whole Maitake mushroom powder and its fractions in two rat strains..” Molecular and cellular biochemistry.Study breakdown →PubMed →↩
5. 5RTHM-00229·Preuss, Harry G et al. (2007). “Enhanced insulin-hypoglycemic activity in rats consuming a specific glycoprotein extracted from maitake mushroom..” Molecular and cellular biochemistry.Study breakdown →PubMed →↩
6. 6RTHM-00262·Preuss, Harry G et al. (2012). “Fraction SX of maitake mushroom favorably influences blood glucose levels and blood pressure in streptozotocin-induced diabetic rats..” Journal of medicinal food.Study breakdown →PubMed →↩
7. 7RTHM-00533·Konno, Sensuke et al. (2013). “Possible hypoglycemic action of SX-fraction targeting insulin signal transduction pathway..” International journal of general medicine.Study breakdown →PubMed →↩
8. 8RTHM-01222·Konno, Sensuke (2020). “SX-fraction: Promise for novel treatment of type 2 diabetes..” World journal of diabetes.Study breakdown →PubMed →↩